Lawrence Kurzius - Mar 31, 2023 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role: Director
Signature: /s/ Catherine S. Powell, as Attorney-in-Fact for Lawrence Kurzius
Stock symbol: ELAN
Transactions as of: Mar 31, 2023
Transactions value $: $27,500
Form type: 4
Date filed: 4/4/2023, 04:32 PM
Previous filing: Mar 31, 2023
Next filing: Apr 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELAN	Deferred Stock Units	Award	$27.5K	+2.93K	+19.23%	$9.40	18.1K	Mar 31, 2023	Common Stock	2.93K		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.
F2	The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
F3	The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $9.40 on March 31, 2023.